A recent study indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a leading medical journal points out that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing such treatments should be aware of the potential of rapid weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass within about 18 months.
Comparing Approaches
The research, which looked at dozens of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through dieting typically have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Doctors suggest the way of the jabs is key to understanding the heightened rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations far above than normal may cause the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
Health authorities suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, given the significant potential of relapse, the treatment might need to be long-term.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
Users who have stopped the medication report a intense resurgence of hunger.
"It felt as if a switch that goes on and I was suddenly ravenous," said a patient.
This difficulty is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Interest
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Finally, researchers caution that while these medications are potent tools for shedding pounds, they are not a permanent fix and long-term success likely depends on integrated behavioural changes.
